Literature DB >> 9130887

Pathologic changes in gonadotropin releasing hormone agonist analogue treated uterine leiomyomata.

L Deligdisch1, S Hirschmann, A Altchek.   

Abstract

OBJECTIVE: To define the pathologic changes underlying the mechanism of shrinkage of uterine leiomyomata in patients treated with luprolide acetate.
DESIGN: Retrospective study of pathologic changes seen in leiomyomata removed by hysterectomy or myomectomy in treated and untreated patients, matched by age and size of uteri and leiomyomata. PATIENT(S): Gross description and histologic slides of 30 treated and 30 untreated patients. INTERVENTION(S): Histologic examination performed blindly (without knowledge of treatment). Statistical work-up using chi 2 analysis with 1 df. MAIN OUTCOME MEASURE(S): Degree of hyaline and hydropic degeneration, cellularity, nuclear atypia, necrosis, and obliteration of interface. RESULT(S): Confluent nodular hyaline degeneration representing a scarlike retraction, geographic hydropic degeneration necrosis and obliteration of the interface between myoma and myometrium were found in higher proportions in the treated patients; differences in cellularity, nuclear atypia, and edema were not statistically significant. CONCLUSION(S): The decrease in size of the treated leiomyomata occurs as an accelerated postmenopausal shrinkage because of the antiestrogenic effect of the therapy. Obliterated cleavage planes may explain the difficult enucleation of myomatous nodules in some of the treated patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9130887     DOI: 10.1016/s0015-0282(97)81394-5

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  9 in total

Review 1.  Medical treatment of uterine leiomyoma.

Authors:  Mohamed Sabry; Ayman Al-Hendy
Journal:  Reprod Sci       Date:  2012-02-28       Impact factor: 3.060

2.  Ultrasound guided high-intensity focused ultrasound combined with gonadotropin releasing hormone analogue (GnRHa) ablating uterine leiomyoma with homogeneous hyperintensity on T2 weighted MR imaging.

Authors:  Shenghua Yang; Fanjing Kong; Ruijie Hou; Fengmei Rong; Nana Ma; Shaoping Li; Jun Yang
Journal:  Br J Radiol       Date:  2017-03-03       Impact factor: 3.039

3.  Assessment of the physical properties of laparoscopic myoma-fixation devices.

Authors:  H Tintara; P Aiyarak; W Mitarnun; A Geater
Journal:  Surg Endosc       Date:  2004-10-26       Impact factor: 4.584

4.  Patient selection guidelines in MR-guided focused ultrasound surgery of uterine fibroids: a pictorial guide to relevant findings in screening pelvic MRI.

Authors:  Sang-Wook Yoon; Chan Lee; Sun Hee Cha; Jeong-Sik Yu; Young-Jeong Na; Kyoung Ah Kim; Sang-Geun Jung; Seung-Jo Kim
Journal:  Eur Radiol       Date:  2008-07-11       Impact factor: 5.315

5.  Treatment of symptomatic uterine fibroids with green tea extract: a pilot randomized controlled clinical study.

Authors:  Eman Roshdy; Veera Rajaratnam; Sarbani Maitra; Mohamed Sabry; Abdou S Ait Allah; Ayman Al-Hendy
Journal:  Int J Womens Health       Date:  2013-08-07

6.  Assisted Reproductive Techniques and submucous myoma.

Authors:  Roshan Nikbakht; Parvin Dorfeshan
Journal:  JBRA Assist Reprod       Date:  2021-10-04

7.  Possible significance of degeneration and decreased expression of progesterone receptor in postmenopausal uterine leiomyoma.

Authors:  Saki Tanioka; Ryoko Asano; Reina Wakabayashi; Hiroyuki Hayashi; Hiroyuki Shigeta
Journal:  BMC Womens Health       Date:  2022-08-16       Impact factor: 2.742

Review 8.  The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis.

Authors:  Elizabeth A Pritts; David J Vanness; Jonathan S Berek; William Parker; Ronald Feinberg; Jacqueline Feinberg; David L Olive
Journal:  Gynecol Surg       Date:  2015-05-19

Review 9.  Uterine fibroids: current perspectives.

Authors:  Aamir T Khan; Manjeet Shehmar; Janesh K Gupta
Journal:  Int J Womens Health       Date:  2014-01-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.